Personalised Cancer Vaccine Cuts Risk of Melanoma Returning in Trial

A clinical trial has shown that a personalised cancer vaccine, used alongside immunotherapy, reduced the risk of death or melanoma recurrence by 42 per cent.

The finding points to the potential of combining a vaccine tailored to an individual patient with treatment that helps the immune system fight cancer.

The reported reduction applies to a combined measure of death or the cancer returning. It does not mean that the risk of each outcome fell separately by 42 per cent.

The available summary did not specify the trial’s size, follow-up period or safety findings. Further details would be needed to assess how widely the results could apply to people with melanoma.